We are live on ! Find out more

Anavex Life Sciences

AVXL

Market cap $243M

2.62 USD

-0.04

1.5%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

2.62

0.00

0%

1 day

-1.5%

5 days

-7.09%

1 month

-25.36%

3 months

4.8%

6 months

-43.66%

Year to date

-28.8%

1 year

-72.65%

5 years

-85.55%

10 years

-12.96%

About: Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Employees: 34

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign

CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex" or the "Company"), today announced that it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors at the upcoming 2026 Annual Meeting of Stockholders.

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign

Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript

Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript

Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript

PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)

CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (Nasdaq: AVXL "Anavex" or the "Company"), believes the Anavex Board of Directors should be replaced and an experienced CEO should be hired.

PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company's clinical development strategy and priorities.

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the Securities and Exchange Commission (“SEC”).

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.'s 2026 Annual Meeting

CENTENNIAL, Colo., Sept. 01, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corporation (“PVG”), together with the other participants named below, has filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GOLD Universal Proxy Card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies from stockholders of Anavex Life Sciences Corp. (Nasdaq: AVXL) (the “Company”) for the Company's 2026 annual meeting of shareholders, including any adjournments, postponements, continuations, reschedulings or any other meeting held in lieu thereof (the “2026 Annual Meeting”).

PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.'s 2026 Annual Meeting

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer's Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today reported a business update and financial results for its third fiscal quarter ended June 30, 2026. “I am delighted to report on the continued regulatory momentum we are building across our pipeline.

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees

Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders

Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company's primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company's clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer's disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™